Illumina, Inc. (NASDAQ: ILMN) today announced the successful completion of the spin-off of GRAIL. This milestone follows the company's previously announced plans to divest GRAIL, and GRAIL is now ...

The judgment confirms Illumina’s longstanding view that the European Commission exceeded its authority by asserting jurisdiction over this merger.. The basis for the $476.96 million (432 million ...

Illumina has unveiled a new spatial technology that is designed to unlock further sequencing capabilities for researchers.

SPIN Art Gallery celebrated the works of a local artist, Izrah Berida, in its homebase at Cafe Lupe Antipolo in her first one-woman show. Berida's first immersive solo exhibition, titled "Tales of ...

Illumina has now completed its GRAIL spin-off and can return to a BAU environment in which it has historically thrived. See why ILMN stock is a Buy.

Dec 17 (Reuters) - Gene sequencing company Illumina , opens new tab said on Sunday it will divest cancer diagnostic test maker Grail , opens new tab after the companies battled both U.S. and ...

Illumina also said it would take a $420 million charge for GRAIL's in-process R&D. Illumina's purchase of GRAIL prior to regulatory approval had been steeped in controversy for years.

Illumina’s stock closed Wednesday at $84.20 per share, down 32 cents. Its stock value is down about 36% year to date, as the company has also been trying to rebound from its failed $7.1 ...

Illumina is getting a new chief financial officer, the latest major leadership change within the past 12 months for the San Diego biotechnology company. Ankur Dhingra will take over as Illumina ...

Davies joined Illumina in 2009. He most recently served as vice president for legal, chief corporate counsel and assistant secretary. Tagged: Charles Dadswell , DNA sequencing , European ...

In its earnings report for 2022, Illumina mentioned it has set aside $458 million—10% of its annual revenue for the year—for a potential EU fine. Key Background.

Illumina Inc. was hit with a €432 million ($476 million) fine for acquiring cancer-test provider Grail Inc. before it was vetted by the European Union, in a test of the bloc’s regulatory power ...